What Researchers Did
The authors described the problem of chronic wounds and diabetic foot ulcers treated with hyperbaric oxygen therapy, including how hard it is to tell early which patients will respond.
What They Found
This clinical study abstract describes hyperbaric oxygen therapy (HBO2T) for chronic wounds and reports that 30-40% of patients with Wagner's Grade 3 and 4 diabetic foot ulcers treated with HBO2T fail to heal by 24 weeks. It states that more than $25 billion per year in the US is spent caring for patients with chronic wounds. It describes HBO2T as a mainstay in healing wounds in specialized wound centers, but also as costly, with a typical course running into the tens of thousands of dollars. A course is described as 30-60 daily treatments over 6-10 weeks. Doctors currently use clinical markers, diagnostic testing and a four-week preliminary healing response, which the abstract calls inaccurate. This delays identifying who responds and who does not.
What This Means for Canadian Patients
For people with diabetic foot ulcers, the abstract shows that a sizable share of those with Grade 3 and 4 ulcers do not heal by 24 weeks even after HBO2T. Patients may complete a long course of treatment before the wound is judged non-responsive. The abstract does not report new test results or compare HBO2T with other care.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract gives background figures and does not report a new patient group, a comparison group or test results, so it cannot show how well HBO2T works.